Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 01, 2026
TickeronGET DAILY SIGNALS
Microbot Medical (MBOT): Can Shares Reach the $5.40 Target for a +395% Gain?

Microbot Medical (MBOT): Can Shares Reach the $5.40 Target for a +395% Gain?

Key Takeaways

  • The central price target of $5.40 is the arithmetic mean of four verified analyst price targets collected from individual firm reports, not a single headline estimate.
  • At roughly $1.09, the shares would need to gain about 395% to reach $5.40 — a very large move by any standard.
  • The analyst target range is unusually wide, spanning from $2.50 to $12.00, reflecting deep disagreement about how fast LIBERTY adoption will translate into revenue.
  • The strongest support comes from FDA clearance, the transition to full market release, and a cash-rich balance sheet; the biggest risks are minimal current revenue, ongoing losses, and a bearish short-seller thesis.
  • Explore more detail on the ticker's Major News, Today's Price Move, Forecast, and Earnings.
  • For automated, AI-driven trade ideas across the broader market, explore Trending AI Robots.

Analyst Price Targets and Consensus View

Four current, attributable analyst targets were reviewed to calculate the central figure. H.C. Wainwright reiterated a Buy rating with a $12.00 target in late October 2026, while Citizens JMP initiated coverage at $2.50. Lucid Capital lowered its target to $3.00 from $4.00 in late September 2026, and B. Riley Securities maintained a Buy at $4.00. The arithmetic mean of these four figures is about $5.38, rounded to a $5.40 average analyst price target, with a range of $2.50 to $12.00.

The spread matters. The $12.00 target — the highest — reflects a more aggressive view of LIBERTY's commercial ramp and international expansion, whereas the $2.50-to-$4.00 cluster reflects more conservative modeling of a very early-stage revenue story. Because the high target pulls the average upward, the mean is meaningfully above the midpoint of the range, and investors should read it as a statistical center rather than a guarantee. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Current Market Position and Path Toward the Target

With shares near $1.09 and a market capitalization around $75 million, MBOT sits far below its 52-week high and well under the $5.40 target. Reaching that level would require a move of roughly 395% — a very large gain that would effectively require the market to re-rate the company from a speculative micro-cap into a credible growth story with demonstrated commercial traction.

The path would likely depend on sustained revenue acceleration, not just product clearance. LIBERTY received FDA 510(k) clearance in September 2025, completed a limited market release, and transitioned to full market release in April 2026. Adoption by systems such as Emory Healthcare and Tampa General Hospital provides early validation, but reported revenue remains minimal, and management does not expect positive gross margins until 2027.

What Could Support a Move Toward the Target

  • LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, a differentiated position in a large market the company pegs at roughly 2.5 million annual U.S. procedures.
  • The expansion to eight sales territories, with a goal of 12 by the end of 2026, and growing engagement with hospital Value Analysis Committees could accelerate adoption.
  • Israel granted marketing clearance in May 2026, and the company anticipates CE mark approval in Europe by late 2026 or early 2027, opening a sizable addressable market.
  • The balance sheet remains strong, with roughly $67 million in cash, reducing near-term financing overhang and supporting the commercial buildout.

What Could Prevent the Target From Being Reached

  • Revenue is still negligible relative to the valuation, and the company continues to generate substantial operating losses, leaving execution risk on the commercial ramp.
  • The path from FDA clearance to broad hospital adoption involves long sales cycles and budget-committee reviews, which can delay revenue inflection.
  • A widely circulated bearish research piece in 2026 questioned LIBERTY's commercial viability, and the company's response has not fully resolved that debate among investors.
  • Competition in vascular robotics remains a factor, and future equity raises to fund growth could dilute existing shareholders.

Technical Levels and Market Structure

MBOT has traded within a broad 52-week range, with support near its 52-week low around $0.93 and a 52-week high near $2.86. The $1.00 level is a psychological support zone, while any move toward the target would first need to reclaim the $2.00 area and then the 52-week high, each representing meaningful overhead resistance. With a small float and frequent double-digit percentage daily swings, the stock's technical structure favors sharp, liquidity-driven moves in both directions. From what I see, monitoring these levels closely helps frame realistic expectations.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month horizon, though the wide range here signals materially different assumptions about the timing of commercial adoption. Key items to watch include quarterly revenue progression, the number of active hospital accounts and repeat usage, progress toward positive gross margins in 2027, the anticipated CE mark decision, and any analyst target revisions following earnings. Given the company's Israel-based operations, any escalation of regional geopolitical tensions is also worth monitoring. I’m watching this closely as new data emerges.

Leveraging Tickeron’s AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile name like MBOT, this kind of systematic scanning can help traders spot emerging trends and monitor positions more efficiently than manual chart review alone. In my view, traders looking for a more disciplined way to identify opportunities may find the platform a useful complement to fundamental research.

Final Assessment

The $5.40 target represents the average of four analyst price targets, a figure distorted upward by the $12.00 high estimate from H.C. Wainwright. From roughly $1.09, reaching it would require a very large gain of about 395% — a move that hinges almost entirely on LIBERTY's commercial execution, revenue acceleration, and successful international expansion. The differentiated, FDA-cleared product and strong balance sheet are genuine strengths, but minimal current revenue, persistent losses, and a contested bearish thesis are serious obstacles. The most likely near-term path involves volatile, sentiment-driven trading rather than a smooth advance, and investors should weigh the wide analyst range as evidence of genuine uncertainty rather than consensus conviction.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MBOT

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


MBOT in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 13, 2026

MBOT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 36 cases where MBOT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for MBOT's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 70 cases where MBOT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

Following a +7.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBOT advanced for three days, in 150 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MBOT as a result. In 74 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.

The Moving Average Convergence Divergence Histogram (MACD) for MBOT turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 38 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBOT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for MBOT entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. MBOT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.082) is normal, around the industry mean (4.142). P/E Ratio (-4.440) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (263.158) is also within normal values, averaging (40.124).

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBOT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which specializes in the research, design, development and commercialization of micro-robotics assisted medical technologies

Industry MedicalNursingServices

Industry
Biotechnology
Address
175 Derby Street
Phone
+1 781 875-3605
Employees
43
Web
https://www.microbotmedical.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.